International models of investigator-initiated trials: implications for Japan
Authors:
Open Access
- 25 July 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (12) , 3151-3155
Abstract
Academic/institutional investigator-initiated clinical trials benefit individuals and society by supplementing gaps in industry-sponsored clinical trials. In May 2010, experts from Japan, the Republic of Korea, the UK, and the United States, met at a symposium in Tokyo, Japan, to discuss how policies related to the conduct of clinical trials, which have been shown to be effective, may be applied to other regions of the world. In order to increase the availability of anticancer drugs world-wide, nations including Japan should examine the benefits of increasing the number of investigator-initiated clinical trials. These trials represent one of the most effective ways to translate basic scientific knowledge into clinical practice. These trials should be conducted under GCP guidelines and include Investigational New Drug application submissions with the ultimate goal of future drug approval. To maximize the effectiveness of these trials, a policy to educate health care professionals, cancer patients and their families, and the public in general on the benefits of clinical trials should be strengthened. Finally, policies that expedite the clinical development of novel cancer drugs which have already been shown to be effective in other countries are needed in many nations including Japan to accelerate drug approval.Keywords
Funding Information
- UK, United States, ROK embassies in Tokyo
- US National Cancer Institute
- Health and Global Policy Institute, Japan
This publication has 11 references indexed in Scilit:
- Regulatory Science as a Bridge Between Science and SocietyClinical Pharmacology & Therapeutics, 2011
- The Development of Priority Cervical Cancer Trials A Gynecologic Cancer InterGroup ReportInternational Journal of Gynecological Cancer, 2010
- Practical issues and lessons learned from multi‐regional clinical trials via case examples: a Japanese perspectivePharmaceutical Statistics, 2010
- Multidisciplinary Meeting on Male Breast Cancer: Summary and Research RecommendationsJournal of Clinical Oncology, 2010
- Applying Community-Based Participatory Research Principles and Approaches in Clinical Trials: Forging a New Model for Cancer Clinical ResearchProgress in Community Health Partnerships: Research, Education, and Action, 2010
- Investigator-initiated cancer trials with INDs for approval in JapanNature Reviews Clinical Oncology, 2010
- Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment TrialsJournal of Clinical Oncology, 2009
- Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)Journal of Clinical Oncology, 2009
- Endometrial Cancer State of the Science MeetingInternational Journal of Gynecological Cancer, 2009
- Recommendations for Collection and Handling of Specimens From Group Breast Cancer Clinical TrialsJournal of Clinical Oncology, 2008